-- Matthew Gline, Director, Chief Executive Officer, on April 16, 2026, sold 289,774 shares in Roivant Sciences (ROIV) for $8,449,810. Following the Form 4 filing with the SEC, Gline has control over a total of 16,736,116 common shares of the company, with 16,736,116 shares held directly.
SEC Filing: